Eli Lilly Zepbound Results - Search News

Order byBest matchMost fresh

News

Zepbound beats Wegovy for weight loss

· 2d · on MSN

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Continue reading

· 3d · on MSN

Eli Lilly’s Zepbound shows superior weight loss over Novo Nordisk's Wegovy in trial

· 2d · on MSN

Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Hosted on MSN3d

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase ...

13don MSN

Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

13d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results